News · 26 weeks76+13%
2026-03-012026-08-23
Mix3290d
- Insider16(50%)
- Other8(25%)
- Earnings3(9%)
- SEC Filings3(9%)
- Leadership1(3%)
- Offering1(3%)
Latest news
25 items- PRInsmed to Present at September 2026 Investor ConferencesBRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.These events will be webcasted live and can be accessed by visiting the investor relations section of the Company's website a
- PRBRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease—First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage—BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved BRINSUPRI® (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older. BRINSUPRI, t
- INSIDERDirector Sharoky Melvin Md sold $637,650 worth of shares (5,000 units at $127.53) (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Operating Officer Adsett Roger sold $31,964,810 worth of shares (239,850 units at $133.27) and exercised 239,850 shares at a strike of $20.45 (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Medical Officer Flammer Martina M.D. exercised 27,173 shares at a strike of $21.20 and sold $3,494,838 worth of shares (27,173 units at $128.61) as part of a pre-agreed trading plan (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Insmed IncorporatedSCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)
- SECInsmed Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INSMED Inc (0001104506) (Filer)
- PRInsmed Reports Second-Quarter 2026 Financial Results and Provides Business Update—Total Company Revenues of $425.5 Million for the Second Quarter of 2026——BRINSUPRI® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Quarter of 2026——ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $116.3 Million for the Second Quarter of 2026, Reflecting 8% Growth Over the Second Quarter of 2025——Company Raises 2026 BRINSUPRI Revenue Guidance to $1.25 Billion to $1.40 Billion——Company Reiterates 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million——Company Raises Peak Revenue Estimate for its Three Lead Programs to More than $14 Billion Total——Peak Revenue Estimate Consists of More than $7 Billion for BR
- SECSEC Form 10-Q filed by Insmed Incorporated10-Q - INSMED Inc (0001104506) (Filer)
- INSIDERChair and CEO Lewis William exercised 10,700 shares at a strike of $24.94 and sold $1,134,890 worth of shares (10,700 units at $106.06) as part of a pre-agreed trading plan (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- PRInsmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss financial results and provide a business update.Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Insmed IncorporatedSCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)
- ANALYSTBMO Capital Markets initiated coverage on Insmed with a new price targetBMO Capital Markets initiated coverage of Insmed with a rating of Outperform and set a new price target of $192.00
- SECInsmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - INSMED Inc (0001104506) (Filer)
- PRInsmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0– –Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12––TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study––These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH––Insmed to Host Investor Call Thursday, July 16, 2026, at 8:00 a.m. ET–BRIDGEWATER, N.J., July 16,
- INSIDERChair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,256,084 worth of shares (10,699 units at $117.40) as part of a pre-agreed trading plan (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Medical Officer Flammer Martina M.D. exercised 12,302 shares at a strike of $25.80 and sold $1,352,932 worth of shares (12,302 units at $109.98) as part of a pre-agreed trading plan (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- PRPalvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of DirectorsBrings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease experience, including executive and Board roles at Savara Inc. (NASDAQ:SVRA), Soleno Therapeutics (NASDAQ:SLNO), Strongbridge Biopharma (NASDAQ:SBBP) and Insmed Incorporated (NASDAQ:INSM) WAYNE, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which th
- FDAFDA Approval for ARIKAYCE KIT issued to INSMED INCSubmission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-25) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/25/2026. Application Category: NDA, Application Number: 207356, Application Classification: Labeling
- INSIDERChair and CEO Lewis William sold $2,210,763 worth of shares (21,398 units at $103.32) as part of a pre-agreed trading plan and exercised 21,398 shares at a strike of $24.94 (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERSVP, GM, Global Respiratory Butera Samuele was granted 7,342 shares (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERSEC Form 3 filed by new insider Butera Samuele3 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Legal Officer Smith Michael Alexander sold $173,051 worth of shares (1,806 units at $95.82) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 37,648 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- PRInsmed Appoints Samuele Butera as Senior Vice President, General Manager, Global RespiratoryBRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today. In this new role, Mr. Butera will assume responsibility for leading Insmed's Respiratory Therapeutic Area. Mr. Butera will report to Will Lewis, Chair and Chief Executive Officer, and serve as a member of Insmed's Executive Committee."We are thrilled to welcome Samuele to Insmed," said Will Lewis, Chair and Chief Executiv
- PRNasdaq-100 Index® June 2026 Quarterly ChangesNEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the June 2026 quarterly rebalance of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, June 22, 2026. The following five companies will be added to the Index: Astera Labs, Inc. (NASDAQ:ALAB), CoreWeave, Inc. (NASDAQ:CRWV), Nebius Group N.V. (NASDAQ:NBIS), Rocket Lab Corporation (NASDAQ:RKLB), Teradyne, Inc. (NASDAQ:TER). The following five companies will be removed from the Index: Charter Communications, Inc. (NASDAQ:CHTR), Cognizant Technology Solutions Corporation (NASDAQ:CTSH), Insmed Incorporated (NASDAQ:INSM), Verisk Analytics, Inc. (NASDAQ:VRSK), Z
INSM FAQ
6 questionsWhat does Insmed Incorporated do?
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the...Where does INSM stock trade?
Insmed Incorporated (INSM) is listed on NASDAQ.What sector and industry is INSM in?
Insmed Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INSM?
Insmed Incorporated has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Outperform on 2026-07-21.What companies are similar to INSM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare INSM side-by-side with any of them on Quantisnow.How can I track INSM on Quantisnow?
Quantisnow aggregates Insmed Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INSM to receive live email and push alerts on every new disclosure.